ClinicalTrials.gg
Not yet recruitingNCT04995159Updated Aug 6, 2021

Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

An interventional study of Single anti-platelet therapy and Dual anti-platelet therapy in Coronary Heart Disease, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Not yet recruiting at 114 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-06.

Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 224 studies in Coronary Disease with a site in China — 68 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.

Planned enrollment
20th of 142
2,150 · median 220
Started
2021
with 19 others
No phase
87 of 224
27 open now
Primary completion
2026-01
later than 29 of 77 live
Registered
130th of 224
by date

Among the 224 studies in Coronary Disease with a site in China, this one is the 20th largest by planned enrollment of the 142 interventional ones that give a count, is one of 20 that started in 2021, is one of 87 with no phase, reaches primary completion later than 29 of the 77 other live ones, and was the 130th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

68 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.

Read the detailed description

A total of 2150 subjects are planned to be enrolled in this trial. Subjects meeting the inclusion criteria and without exclusion criteria are implanted with NeoVas™ stents and randomly assigned to the experimental group and the control group in a 1:1 ratio. Patients in both groups will receive aspirin in combination with a P2Y12 receptor antagonist in the first year after PCI (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia). Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery in the experimental group. The control group will continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.

Subjects will be followed up at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years after surgery to observe whether the net adverse clinical events (NACEs) and other end points occur or not.

03

Conditions studied

  • Coronary Heart Disease

Browse trials for

Keywords

  • Bioabsorbable Coronary Artery Rapamycin-eluting Stent System
  • Optimized Antiplatelet Therapy
  • Coronary Heart Disease
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or above, male or non-pregnant female.
  • Evidence of myocardial ischemia (e.g., stable angina, unstable angina, medium-low risk NSTEMI, STEMI with onset more than 1 week, old myocardial infarction or asymptomatic myocardial ischemia), and suitable for PCI surgery.
  • The target lesion is in-situ coronary artery lesion, the total length of single lesion is no more than 40mm (the total length of stent is no more than 48mm), and the diameter of the target lesion is between 2.75mm and 3.75mm (visual measurement).
  • The diameter stenosis of target lesion is ≥70% in visual (or ≥50% with clinical evidence of myocardial ischemia in that range), and the TIMI blood flow is greater than grade 1.
  • The stent with diameter more than 3.0mm is allowed to overlap with another stent once, the overlapping methods could be edge to edge or at most 1mm overlap. The total number of stents per patient is no more than 4, with a maximum of 2 stents per vessel (the 2.75mm diameter stent is not allowed to overlap).
  • Patient with indications for coronary artery bypass surgery.
  • Aspirin and clopidogrel could be used continuously during the study.
  • Patient who can understand the purpose of this trial, is willing to participate in the trial and to conduct clinical follow-up as required by the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Acute ST-segment elevation myocardial infarction within 1 week.
  • Left main coronary artery disease, branch vessel diameter≥2.0mm, three-vessel coronary artery disease and bridge vessel disease; visible thrombus in the target vessel.
  • Severe distortion, severe calcification that cannot be successfully predilated, and other lesions that are not suitable for stent delivery and deployment.
  • Intra-stent restenosis.
  • Severe heart failure (≥III or \<35%).
  • Severe renal insufficiency, \<30ml/min/1.73m2 or serum creatinine>2.5mg/dL (221μmol/L).
  • Patients with bleeding tendency, active gastrointestinal ulcer, history of cerebral hemorrhage or subarachnoid hemorrhage, history of stroke within half a year, fundus hemorrhage affecting vision, antiplatelet agents and anticoagulant treatment who cannot receive antithrombotic therapy.
  • Patients requiring long-term oral anticoagulants during the study period.
  • Patients who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Patients with , organ transplants, or drug addiction that can seriously affect study compliance.
  • Patients with contraindications to aspirin, clopidogrel or ticagrelor.
  • Known allergy to aspirin, clopidogrel, ticagrelor, heparin, contrast agent, polylactic acid polymer and rapamycin.
  • Thrombosis occurred during previous clopidogrel treatment.
  • is less than 36 months.
  • Participated in clinical trials of other drugs or medical devices before enrollment and failed to meet the time limit of the primary end point.
  • Patients who will have elective surgery within a year and need to discontinue aspirin, clopidogrel or ticagrelor.
  • Subjects are deemed unsuitable for enrollment by investigators.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,150 participants (estimated)

Study arms

  • Experimental
    Poststent SAPT treatment cohort

    receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with SAPT strategy

    Drug: Single anti-platelet therapy

  • Active comparator
    Poststent DAPT treatment cohort

    receiving the treatment with NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System of Lepu Medical combined with DAPT strategy

    Drug: Dual anti-platelet therapy

Interventions

  • DrugSingle anti-platelet therapy

    Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.

    Also known as: SAPT strategy

  • DrugDual anti-platelet therapy

    Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.

    Also known as: DAPT strategy

06

What researchers measure

Primary outcomes

  1. Net adverse clinical event (NACE)

    NACE includes POCE (including all-cause death, all non-fatal myocardial infarction (Universal Definition of Myocardial Infarction, 4th Edition), any revascularization, and stroke), and major bleeding events of grade 2, 3, and 5 as defined by BARC.

    Time frame: 3 years

Secondary outcomes

  1. Target lesion failure (TLF)

    Target lesion failure (TLF) includes cardiac death, target vessel myocardial infarction (TV-MI) and ischemic-driven target lesion revascularization (ID-TLR).

    Time frame: 3 years

  2. Comparison of net adverse clinical events

    Time frame: 30 days, 6 months, 1 year, 2 years, 4 years, and 5 years

  3. Bleeding events of grade 3 and 5 as defined by BARC

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  4. Bleeding events of grade 2, 3 and 5 as defined by BARC

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  5. Bleeding events of grade 1, 2, 3 and 5 as defined by BARC

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  6. Comparison of target lesion failures

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  7. Patient-oriented composite endpoint (PoCE)

    Patient-oriented composite endpoint (PoCE) includes all-cause death, all MI, any revascularization, and stroke.

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  8. Ischemic-driven target lesion revascularization (iTLR)

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  9. Ischemic-driven target vessel revascularization (iTVR)

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  10. All cardiac revascularization

    All cardiac revascularization includes PCI and CABG.

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  11. Two types of stent thrombosis events as defined by BRS_ARC2

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years

07

Study locations

114 sites

Showing the first 100 of 114 sites. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2021; primary completion for Jan 2026, 52 months later.

Of 202 interventional studies with no phase under Coronary Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 51. This study's planned 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 6, 2021
StartEst.
Sep 2021
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2028
Last update
Aug 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04995159
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Sep 2021 (estimated)
Primary completion
Jan 2026 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 6, 2021

Study contacts

Ting Zhang
Contact
ting_zhang@lepumedical.com
+86-010-80120666
Yaling Han
study chair · The General Hospital of Northern Theater Command

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion